KNTPF
Price
$0.16
Change
-$0.01 (-5.88%)
Updated
Nov 1 closing price
Capitalization
49.81M
SYRS
Price
$0.22
Change
+$0.02 (+10.00%)
Updated
Jan 17 closing price
Capitalization
5.89M
46 days until earnings call
Ad is loading...

KNTPF vs SYRS

Header iconKNTPF vs SYRS Comparison
Open Charts KNTPF vs SYRSBanner chart's image
KINTOR PHARMACEUTICAL
Price$0.16
Change-$0.01 (-5.88%)
Volume$20K
Capitalization49.81M
Syros Pharmaceuticals
Price$0.22
Change+$0.02 (+10.00%)
Volume$1.18M
Capitalization5.89M
KNTPF vs SYRS Comparison Chart
Loading...
SYRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KNTPF vs. SYRS commentary
Jan 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KNTPF is a Buy and SYRS is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 19, 2025
Stock price -- (KNTPF: $0.16 vs. SYRS: $0.22)
Brand notoriety: KNTPF and SYRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KNTPF: 100% vs. SYRS: 9%
Market capitalization -- KNTPF: $49.81M vs. SYRS: $5.89M
KNTPF [@Biotechnology] is valued at $49.81M. SYRS’s [@Biotechnology] market capitalization is $5.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $368.92B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KNTPF’s FA Score shows that 0 FA rating(s) are green whileSYRS’s FA Score has 1 green FA rating(s).

  • KNTPF’s FA Score: 0 green, 5 red.
  • SYRS’s FA Score: 1 green, 4 red.
According to our system of comparison, KNTPF is a better buy in the long-term than SYRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRS’s TA Score shows that 4 TA indicator(s) are bullish.

  • SYRS’s TA Score: 4 bullish, 2 bearish.

Price Growth

KNTPF (@Biotechnology) experienced а 0.00% price change this week, while SYRS (@Biotechnology) price change was -2.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.44%. For the same industry, the average monthly price growth was +2.66%, and the average quarterly price growth was -1.92%.

Reported Earning Dates

SYRS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-1.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KNTPF($49.8M) has a higher market cap than SYRS($5.89M). KNTPF YTD gains are higher at: 0.000 vs. SYRS (-4.526).
KNTPFSYRSKNTPF / SYRS
Capitalization49.8M5.89M846%
EBITDAN/A-91.14M-
Gain YTD0.000-4.526-
P/E RatioN/AN/A-
RevenueN/A386K-
Total CashN/A58.3M-
Total DebtN/A60.2M-
FUNDAMENTALS RATINGS
SYRS: Fundamental Ratings
SYRS
OUTLOOK RATING
1..100
32
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
66
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
KNTPFSYRS
RSI
ODDS (%)
N/A
Bullish Trend 12 days ago
79%
Stochastic
ODDS (%)
N/A
Bullish Trend 12 days ago
84%
Momentum
ODDS (%)
N/A
Bullish Trend 12 days ago
82%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
36%
Bearish Trend 12 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 12 days ago
31%
Bearish Trend 12 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 14 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 12 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Ad is loading...
SYRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SDVD22.460.04
+0.18%
FT Vest SMID Ris Div Ach Trg IncETF
VGLT55.160.07
+0.13%
Vanguard Long-Term Treasury ETF
IWC129.220.14
+0.11%
iShares Micro-Cap ETF
ARB27.840.01
+0.05%
AltShares Merger Arbitrage ETF
RTAI21.31N/A
N/A
Rareview Tax Advantaged Income ETF

KNTPF and

Correlation & Price change

A.I.dvisor tells us that KNTPF and SYRS have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KNTPF and SYRS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KNTPF
1D Price
Change %
KNTPF100%
N/A
SYRS - KNTPF
31%
Poorly correlated
+7.02%
MLEC - KNTPF
27%
Poorly correlated
-1.29%
KNSA - KNTPF
20%
Poorly correlated
+0.82%
UNCY - KNTPF
20%
Poorly correlated
+0.98%
RLFTY - KNTPF
20%
Poorly correlated
N/A
More

SYRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRS has been loosely correlated with XFOR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRS jumps, then XFOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRS
1D Price
Change %
SYRS100%
+7.02%
XFOR - SYRS
48%
Loosely correlated
+10.06%
ORMP - SYRS
33%
Poorly correlated
-1.72%
KNTPF - SYRS
32%
Poorly correlated
N/A
AXON - SYRS
30%
Poorly correlated
+1.37%
VKTX - SYRS
30%
Poorly correlated
+0.28%
More